{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:34:05Z","timestamp":1791272045165,"version":"4.1.0"},"reference-count":19,"publisher":"Cambridge University Press (CUP)","issue":"S2","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides consensus recommendations on the management of cutaneous basal cell carcinoma and squamous cell carcinoma in the head and neck region on the basis of current evidence.<\/jats:p>\n                  <jats:sec id=\"S0022215116000554_sec_a1\">\n                    <jats:title>Recommendations<\/jats:title>\n                    <jats:p>\u2022 Royal College of Pathologists minimum datasets for NMSC should be adhered to in order to improve patient care and help work-force planning in pathology departments. (G)<\/jats:p>\n                    <jats:p>\u2022 Tumour depth is of critical importance in identifying high-risk cutaneous squamous cell carcinoma (cSCC), and should be reported in all cases. (R)<\/jats:p>\n                    <jats:p>\u2022 Appropriate imaging to determine the extent of primary NMSC is indicated when peri-neural involvement or bony invasion is suspected. (R)<\/jats:p>\n                    <jats:p>\u2022 In the clinically N0 neck, radiological imaging is not beneficial, and a policy of watchful waiting and patient education can be adopted. (R)<\/jats:p>\n                    <jats:p>\u2022 Patients with high-risk NMSC should be treated by members of a skin cancer multidisciplinary team (MDT) in secondary care. (G)<\/jats:p>\n                    <jats:p>\u2022 Non-infiltrative basal cell carcinoma (BCC) &lt;2 cm in size should be excised with a margin of 4\u20135 mm. Smaller margins (2\u20133 mm) may be taken in sites where reconstructive options are limited, when reconstruction should be delayed. (R)<\/jats:p>\n                    <jats:p>\u2022 Where there is a high risk of recurrence, delayed reconstruction or Mohs micrographic surgery should be used. (R)<\/jats:p>\n                    <jats:p>\u2022 Surgical excision of low-risk cSCC with a margin of 4 mm or greater is the treatment of choice. (R)<\/jats:p>\n                    <jats:p>\u2022 High-risk cSCC should be excised with a margin of 6 mm or greater. (R).<\/jats:p>\n                    <jats:p>\u2022 Mohs micrographic surgery has a role in some high-risk cSCC cases following MDT discussion. (R)<\/jats:p>\n                    <jats:p>\u2022 Delayed reconstruction should be used in high-risk cSCC. (G)<\/jats:p>\n                    <jats:p>\u2022 Intra-operative conventional frozen section in cSCC is not recommended. (G)<\/jats:p>\n                    <jats:p>\u2022 Radiotherapy (RT) is an effective therapy for primary BCC and cSCC. (R)<\/jats:p>\n                    <jats:p>\u2022 Re-excision should be carried out for incompletely excised high-risk BCC or where there is deep margin involvement. (R)<\/jats:p>\n                    <jats:p>\u2022 Incompletely excised high-risk cSCC should be re-excised. (R)<\/jats:p>\n                    <jats:p>\u2022 Further surgery should involve confirmed marginal clearance before reconstruction. (R)<\/jats:p>\n                    <jats:p>\u2022 P+ N0 disease: Resection should include involved parotid tissue, combined with levels I\u2013III neck dissection, to include the external jugular node. (R)<\/jats:p>\n                    <jats:p>\u2022 P+ N+ disease: Resection should include level V if that level is clinically or radiologically involved. (R)<\/jats:p>\n                    <jats:p>\u2022 Adjuvant RT should include level V if not dissected. (R)<\/jats:p>\n                    <jats:p>\u2022 P0 N+ disease: Anterior neck disease should be managed with levels I\u2013IV neck dissection to include the external jugular node. (R)<\/jats:p>\n                    <jats:p>\u2022 P0 N+ posterior echelon nodal disease (i.e. occipital or post-auricular) should undergo dissection of levels II\u2013V, with sparing of level I. (R)<\/jats:p>\n                    <jats:p>\u2022 Consider treatment of the ipsilateral parotid if the primary site is the anterior scalp, temple or forehead. (R)<\/jats:p>\n                    <jats:p>\u2022 All patients should receive education in self-examination and skin cancer prevention measures. (G)<\/jats:p>\n                    <jats:p>\u2022 Patients who have had a single completely excised BCC or low-risk cSCC can be discharged after a single post-operative visit. (G)<\/jats:p>\n                    <jats:p>\u2022 Patients with an excised high-risk cSCC should be reviewed three to six monthly for two years, with further annual review depending upon clinical risk. (G)<\/jats:p>\n                    <jats:p>\u2022 Those with recurrent or multiple BCCs should be offered annual review. (G)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s0022215116000554","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T06:37:06Z","timestamp":1463035026000},"page":"S125-S132","source":"Crossref","is-referenced-by-count":168,"title":["Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines"],"prefix":"10.1017","volume":"130","author":[{"given":"C","family":"Newlands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Woolford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"S0022215116000554_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2014.01.015"},{"key":"S0022215116000554_ref19","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20608"},{"key":"S0022215116000554_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08666.x"},{"key":"S0022215116000554_ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLG.0000158349.64337.ED"},{"key":"S0022215116000554_ref7","volume-title":"Dataset for the Histological Reporting of Primary Invasive Cutaneous Squamous Cell Carcinoma and Regional Lymph Nodes","author":"Slater","year":"2014"},{"key":"S0022215116000554_ref11","doi-asserted-by":"publisher","DOI":"10.1054\/bjom.2000.0322"},{"key":"S0022215116000554_ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20417"},{"key":"S0022215116000554_ref1","volume-title":"Improving Outcomes for People with Skin Tumours Including Melanoma","year":"2006"},{"key":"S0022215116000554_ref8","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2009"},{"key":"S0022215116000554_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11798"},{"key":"S0022215116000554_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-013-0041-2"},{"key":"S0022215116000554_ref5","volume-title":"Improving Outcomes for People with Skin Tumours including Melanoma (update). The Management of Low-risk Basal Cell Carcinomas in the Community","year":"2006"},{"key":"S0022215116000554_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2009.07.007"},{"key":"S0022215116000554_ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000312649"},{"key":"S0022215116000554_ref10","first-page":"CD003412","article-title":"Interventions for basal cell carcinoma of the skin","author":"Bath-Hextall","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"S0022215116000554_ref3","volume-title":"Management of the Patient with Primary Squamous Cell Carcinoma","year":"2009"},{"key":"S0022215116000554_ref4","volume-title":"Management of Primary Cutaneous Squamous Cell Carcinoma","year":"2014"},{"key":"S0022215116000554_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2139"},{"key":"S0022215116000554_ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5326"}],"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0022215116000554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T15:35:38Z","timestamp":1555688138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0022215116000554\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":19,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0022215116000554"],"URL":"https:\/\/doi.org\/10.1017\/s0022215116000554","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}